- MaxCyte (NASDAQ:MXCT) said on Monday that it has signed a strategic platform license with Adicet Bio, a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
- Under the terms of the
MaxCyte signs platform license agreement with Adicet Bio
.png)
14 hours ago
1
Related
Laxmi India Finance IPO set for debut today. Check GMP ahead...
43 minutes ago
0
Sources: Raiders trade CB Bennett to Eagles
47 minutes ago
0
Aditya Infotech IPO set to list today. GMP at 45% signals ro...
53 minutes ago
0
Popular
Listen to the sounds of a black hole with these NASA sonific...
2 months ago
75
Palm Springs Bombing: What We Know About Fertility Clinic Ex...
2 months ago
66
Oil futures fall as Saudi Arabia said to seek more big OPEC ...
2 months ago
49
This is the next historical period I want to see in Assassin...
2 months ago
44
UK's unemployment rate rises to 4.6% in April
1 month ago
41
English (US) · © Insaro Search Engines 2025. All rights are reserved